Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency
May 23, 2016 16:00 ET
|
Aeglea Biotherapeutics
AUSTIN, Texas, May 23, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics To Present at the UBS 2016 Global Healthcare Conference
May 20, 2016 16:00 ET
|
Aeglea Biotherapeutics
AUSTIN, Texas, May 20, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results
May 19, 2016 06:00 ET
|
Aeglea Biotherapeutics
AUSTIN, Texas, May 19, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer
May 16, 2016 08:00 ET
|
Aeglea Biotherapeutics
AUSTIN, Texas, May 16, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc., (NASDAQ:AGLE) a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
April 19, 2016 09:00 ET
|
Aeglea Biotherapeutics
AUSTIN, Texas, April 19, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics to Present New Data at American Association for Cancer Research (AACR) Annual Meeting
April 18, 2016 09:00 ET
|
Aeglea Biotherapeutics
AUSTIN, Texas, April 18, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...
Aeglea BioTherapeutics Announces Closing of Initial Public Offering and Partial Exercise of the Underwriters’ Option
April 12, 2016 16:00 ET
|
Aeglea Biotherapeutics
AUSTIN, Texas, April 12, 2016 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a biotechnology company committed to developing enzyme-based therapeutics in the field of amino acid...